Chikujee Therapeutics is focused on designing, developing and commercializing next generation therapeutics using our patent-pending class of multifunctional nanoparticles. Chikujee uses NanoBindi™ based integrated disease management platform that is based on our proprietary BOSH-containing polymers. We are developing Target Specific NanoMedicines, with initial focus on using off-patent compounds that have documented efficacy, but which also have known issues relating to their solubility, stability, undesirable side effects or poor pharmacokinetics that we can improve significantly with our proprietary product engines.

Founded in 2008, Chikujee Therapeutics has developed product engines that have broad applications in life-sciences, primarily in bionanotechnology, biotechnology and biopharmaceutical industries. We believe there is significant value in “product engines” – new biological and technological platforms capable of creating products in multiple diseases, which have the potential for broad applications, market leadership and extraordinary value creation. The initial focus of Chikujee Therapeutics will be to develop market leading blockbuster products for integrated cancer management that addresses, targeted drug delivery and monitoring, and clinical efficacy of the drugs for cancer using its proprietary multifunctional NanoBindis.